Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
577.16B
Market cap577.16B
Price-Earnings ratio
22.04
Price-Earnings ratio22.04
Dividend yield
2.14%
Dividend yield2.14%
Average volume
7.22M
Average volume7.22M
High today
$244.00
High today$244.00
Low today
$239.18
Low today$239.18
Open price
$243.60
Open price$243.60
Volume
2.69M
Volume2.69M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

Johnson & Johnson(JNJ) stock is priced at $239.50, giving the company a market capitalization of 577.16B. It carries a P/E multiple of 22.04 and pays a dividend yield of 2.1%.

During the trading session on 2026-03-17, Johnson & Johnson(JNJ) shares reached a daily high of $244.00 and a low of $239.18. At a current price of $239.50, the stock is +0.1% higher than the low and still -1.8% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 2.69M, versus its average volume of 7.22M.

The stock's 52-week range extends from a low of $141.50 to a high of $251.71.

The stock's 52-week range extends from a low of $141.50 to a high of $251.71.

JNJ News

Nasdaq 4h
Dow Movers: JNJ, GS

In early trading on Tuesday, shares of Goldman Sachs Group topped the list of the day's best performing Dow Jones Industrial Average components, trading up 2.8%...

Dow Movers: JNJ, GS
TipRanks 6h
Johnson & Johnson price target raised to $280 from $245 at UBS

UBS analyst Danielle Antalffy raised the firm’s price target on Johnson & Johnson to $280 from $245 and keeps a Buy rating on the shares. Published first on Th...

The Motley Fool 1d
Your Tax Refund Will Probably Be Bigger This Year. Here's What to Do With It.

Due to the "big, beautiful bill" passed last year, many taxpayers can expect a larger refund from the Internal Revenue Service this tax season. That's because t...

Your Tax Refund Will Probably Be Bigger This Year. Here's What to Do With It.

Analyst ratings

59%

of 29 ratings
Buy
58.6%
Hold
34.5%
Sell
6.9%

More JNJ News

TipRanks 1d
J&J announces Phase 1 study of erdafitinib met primary safety endpoint

Johnson & Johnson announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafiti...

TipRanks 1d
Monte Rosa Therapeutics announces clinical supply agreement with Johnson & Johnson

Monte Rosa Therapeutics (GLUE) announced the company has entered into a supply agreement with Johnson & Johnson to evaluate MRT-2359 in combination with ERLEADA...

Simply Wall St 4d
Johnson And Johnson Bladder Cancer Data Adds Interest To Valuation Story

Johnson & Johnson (NYSE:JNJ) reported strong Phase 1 results for its intravesical erdafitinib drug releasing system in non muscle invasive bladder cancer. The...

Johnson And Johnson Bladder Cancer Data Adds Interest To Valuation Story
Nasdaq 4d
Johnson & Johnson Reports Promising Phase 1 Results For Erda-iDRS In Early-Stage Bladder Cancer

(RTTNews) - Johnson & Johnson (JNJ) announced new data from an open-label, multicenter Phase 1 study evaluating Erda-iDRS, an investigational intravesical drug-...

Johnson & Johnson Reports Promising Phase 1 Results For Erda-iDRS In Early-Stage Bladder Cancer
TipRanks 4d
J&J says erdafitinib met primary safety endpoint in Phase 1 study

Johnson & Johnson announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafiti...

Simply Wall St 5d
Is Johnson & Johnson Pricing Reflect Its Strong Multi‑Year Rally And Legal Headline Risks

Wondering whether Johnson & Johnson is fairly priced at its current level, or if the market is missing something in this healthcare giant's story? The stock re...

Is Johnson & Johnson Pricing Reflect Its Strong Multi‑Year Rally And Legal Headline Risks
The Motley Fool 5d
The Best Dividend Stocks to Buy and Hold Forever

Dividend investing is a proven way to grow your wealth over the long run. But for the strategy to work, investors need to pick quality income stocks, those with...

The Best Dividend Stocks to Buy and Hold Forever

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.